Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1.


Journal

Nature immunology
ISSN: 1529-2916
Titre abrégé: Nat Immunol
Pays: United States
ID NLM: 100941354

Informations de publication

Date de publication:
02 2020
Historique:
received: 15 02 2019
accepted: 10 12 2019
pubmed: 22 1 2020
medline: 14 4 2020
entrez: 22 1 2020
Statut: ppublish

Résumé

Human leukocyte antigen (HLA)-independent, T cell-mediated targeting of cancer cells would allow immune destruction of malignancies in all individuals. Here, we use genome-wide CRISPR-Cas9 screening to establish that a T cell receptor (TCR) recognized and killed most human cancer types via the monomorphic MHC class I-related protein, MR1, while remaining inert to noncancerous cells. Unlike mucosal-associated invariant T cells, recognition of target cells by the TCR was independent of bacterial loading. Furthermore, concentration-dependent addition of vitamin B-related metabolite ligands of MR1 reduced TCR recognition of cancer cells, suggesting that recognition occurred via sensing of the cancer metabolome. An MR1-restricted T cell clone mediated in vivo regression of leukemia and conferred enhanced survival of NSG mice. TCR transfer to T cells of patients enabled killing of autologous and nonautologous melanoma. These findings offer opportunities for HLA-independent, pan-cancer, pan-population immunotherapies.

Identifiants

pubmed: 31959982
doi: 10.1038/s41590-019-0578-8
pii: 10.1038/s41590-019-0578-8
pmc: PMC6983325
mid: EMS85172
doi:

Substances chimiques

Histocompatibility Antigens Class I 0
MR1 protein, human 0
Minor Histocompatibility Antigens 0
Receptors, Antigen, T-Cell 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

178-185

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 100327
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L008742/1
Pays : United Kingdom
Organisme : NIDDK NIH HHS
ID : U54 DK110858
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : ErratumIn

Références

Vavassori, S. et al. Butyrophilin 3A1 binds phosphorylated antigens and stimulates human γδ T cells. Nat. Immunol. 14, 908–916 (2013).
doi: 10.1038/ni.2665
Kjer-Nielsen, L. et al. MR1 presents microbial vitamin B metabolites to MAIT cells. Nature 491, 717–723 (2012).
doi: 10.1038/nature11605
Corbett, A. J. et al. T-cell activation by transitory neo-antigens derived from distinct microbial pathways. Nature 509, 361–365 (2014).
doi: 10.1038/nature13160
Gold, M. C. et al. MR1-restricted MAIT cells display ligand discrimination and pathogen selectivity through distinct T cell receptor usage. J. Exp. Med. 211, 1601–1610 (2014).
doi: 10.1084/jem.20140507
Eckle, S. B. G. et al. Recognition of vitamin B precursors and byproducts by mucosal associated invariant T cells. J. Biol. Chem. 290, 30204–30211 (2015).
doi: 10.1074/jbc.R115.685990
Le Bourhis, L. et al. Antimicrobial activity of mucosal-associated invariant T cells. Nat. Immunol. 11, 701–708 (2010).
doi: 10.1038/ni.1890
Reantragoon, R. et al. Structural insight into MR1-mediated recognition of the mucosal associated invariant T cell receptor. J. Exp. Med. 209, 761–774 (2012).
doi: 10.1084/jem.20112095
Lepore, M. et al. Parallel T-cell cloning and deep sequencing of human MAIT cells reveal stable oligoclonal TCRβ repertoire. Nat. Commun. 5, 3866 (2014).
doi: 10.1038/ncomms4866
Lepore, M. et al. Functionally diverse human T cells recognize non-microbial antigens presented by MR1. eLife 6, 1–22 (2017).
Gherardin, N. A. et al. Diversity of T cells restricted by the MHC class I-related molecule MR1 facilitates differential antigen recognition. Immunity 44, 32–45 (2016).
doi: 10.1016/j.immuni.2015.12.005
Keller, A. N. et al. Drugs and drug-like molecules can modulate the function of mucosal-associated invariant T cells. Nat. Immunol. 18, 402–411 (2017).
doi: 10.1038/ni.3679
Reantragoon, R. et al. Antigen-loaded MR1 tetramers define T cell receptor heterogeneity in mucosal-associated invariant T cells. J. Exp. Med. 210, 2305–2320 (2013).
doi: 10.1084/jem.20130958
McWilliam, H. E. G. et al. The intracellular pathway for the presentation of vitamin B-related antigens by the antigen-presenting molecule MR1. Nat. Immunol. 17, 531–537 (2016).
doi: 10.1038/ni.3416
Lamichhane, R. & Ussher, J. E. Expression and trafficking of MHC related protein 1 (MR1). J. Immunol. 38, 42–49 (2017).
Young, M. H. et al. MAIT cell recognition of MR1 on bacterially infected and uninfected cells. PLoS ONE 8, e53789 (2013).
doi: 10.1371/journal.pone.0053789
Gentles, A. J. et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med. 21, 938–945 (2015).
doi: 10.1038/nm.3909
Gherardin, N. A. et al. Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma. Sci. Rep. 8, 4159 (2018).
doi: 10.1038/s41598-018-22130-1
Parra-Cuadrado, J. F. et al. A study on the polymorphism of human MHC class I-related MR1 gene and identification of an MR1-like pseudogene. Tissue Antigens 56, 170–172 (2000).
doi: 10.1034/j.1399-0039.2000.560211.x
Seshadri, C. et al. A polymorphism in human MR1 is associated with mRNA expression and susceptibility to tuberculosis. Genes Immun. 18, 8–14 (2017).
doi: 10.1038/gene.2016.41
Lion, J. et al. MR1B, a natural spliced isoform of the MHC-related 1 protein, is expressed as homodimers at the cell surface and activates MAIT cells. Eur. J. Immunol. 43, 1363–1373 (2013).
doi: 10.1002/eji.201242461
Shalem, O. et al. Genome-scale CRISPR–Cas9 knockout screening in human cells. Science 343, 84–87 (2014).
doi: 10.1126/science.1247005
Patel, S. J. et al. Identification of essential genes for cancer immunotherapy. Nature 548, 537–542 (2017).
doi: 10.1038/nature23477
Reith, W., LeibundGut-Landmann, S. & Waldburger, J.-M. Regulation of MHC class II gene expression by the class II transactivator. Nat. Rev. Immunol. 5, 793–806 (2005).
doi: 10.1038/nri1708
Laugel, B. et al. Engineering of isogenic cells deficient for MR1 with a CRISPR/Cas9 lentiviral system: tools to study microbial antigen processing and presentation to human MR1-restricted T cells. J. Immunol. 197, 971–982 (2016).
doi: 10.4049/jimmunol.1501402
Eckle, S. B. G. et al. A molecular basis underpinning the T cell receptor heterogeneity of mucosal-associated invariant T cells. J. Exp. Med. 211, 1585–1600 (2014).
doi: 10.1084/jem.20140484
Alía, M., Ramos, S., Mateos, R., Bravo, L. & Goya, L. Response of the antioxidant defense system to tert-butyl hydroperoxide and hydrogen peroxide in a human hepatoma cell line (HepG2). J. Biochem. Mol. Toxicol. 19, 119–128 (2005).
doi: 10.1002/jbt.20061
Irvine, D. J., Purbhoo, M. A., Krogsgaard, M. & Davis, M. M. Direct observation of ligand recognition by T cells. Nature 419, 845–849 (2002).
doi: 10.1038/nature01076
Hulin-Curtis, S. L. et al. Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic adenovirus. Oncotarget 9, 26328–26341 (2018).
doi: 10.18632/oncotarget.25242
Wooldridge, L. et al. MHC class I molecules with superenhanced CD8 binding properties bypass the requirement for cognate TCR recognition and nonspecifically activate CTLs. J. Immunol. 184, 3357–3366 (2010).
doi: 10.4049/jimmunol.0902398
Lissina, A. et al. Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers. J. Immunol. Methods 340, 11–24 (2009).
doi: 10.1016/j.jim.2008.09.014
Tungatt, K. et al. Antibody stabilization of peptide-MHC multimers reveals functional T cells bearing extremely low-affinity TCRs. J. Immunol. 194, 463–474 (2014).
doi: 10.4049/jimmunol.1401785
Betts, M. R. et al. Sensitive and viable identification of antigen-specific CD8
doi: 10.1016/S0022-1759(03)00265-5
Haney, D. et al. Isolation of viable antigen-specific CD8
doi: 10.1016/j.jim.2011.04.003
Ryan, M. D., King, A. M. Q. & Thomas, G. P. Cleavage of foot-and-mouth disease virus polyprotein is mediated by residues located within a 19 amino acid sequence. J. Gen. Virol. 72, 2727–2732 (1991).
doi: 10.1099/0022-1317-72-11-2727
Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783–784 (2014).
doi: 10.1038/nmeth.3047
Li, W. et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. Genome Biol. 15, 554 (2014).
doi: 10.1186/s13059-014-0554-4
Maciocia, P. M. et al. Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies. Nat. Med. 23, 1416–1423 (2017).
doi: 10.1038/nm.4444

Auteurs

Michael D Crowther (MD)

Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.

Garry Dolton (G)

Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.

Mateusz Legut (M)

Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.

Marine E Caillaud (ME)

Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.

Angharad Lloyd (A)

Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.

Meriem Attaf (M)

Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.

Sarah A E Galloway (SAE)

Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.

Cristina Rius (C)

Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.

Colin P Farrell (CP)

Division of Hematology, University of Utah School of Medicine, Salt Lake City, UT, USA.

Barbara Szomolay (B)

Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.
Systems Immunity Research Institute, Cardiff University, Cardiff, UK.

Ann Ager (A)

Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.
Systems Immunity Research Institute, Cardiff University, Cardiff, UK.

Alan L Parker (AL)

Division of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, UK.

Anna Fuller (A)

Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.

Marco Donia (M)

Center for Cancer Immune Therapy, Herlev Hospital, Copenhagen University, Copenhagen, Denmark.

James McCluskey (J)

Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria, Australia.

Jamie Rossjohn (J)

Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.
Systems Immunity Research Institute, Cardiff University, Cardiff, UK.
Australian Research Council Centre of Excellence in Advanced Molecular Imaging, Monash University, Clayton, Victoria, Australia.
Infection and Immunity Program & Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.

Inge Marie Svane (IM)

Center for Cancer Immune Therapy, Herlev Hospital, Copenhagen University, Copenhagen, Denmark.

John D Phillips (JD)

Division of Hematology, University of Utah School of Medicine, Salt Lake City, UT, USA.

Andrew K Sewell (AK)

Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK. sewellak@cardiff.ac.uk.
Systems Immunity Research Institute, Cardiff University, Cardiff, UK. sewellak@cardiff.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH